[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.30. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 4,909
Citations 0
Viewpoint
Annual Meeting Highlights
October 2016

Recent Developments in Melanoma Therapy

Author Affiliations
  • 1Melanoma Institute Australia, Sydney, Australia
  • 2The University of Sydney, Sydney, Australia
  • 3Royal North Shore Hospital, Sydney, Australia
  • 4Mater Hospital, Sydney, Australia
JAMA Oncol. 2016;2(10):1259-1260. doi:10.1001/jamaoncol.2016.3418

During the last 10 years, we have witnessed success after success for the treatment of advanced melanoma, and data presented at the 2016 American Society of Clinical Oncology (ASCO) annual meeting continued this upward trend. While impressive long-term overall and progression-free survival (PFS) data were presented for patients with advanced melanoma treated with both immune and targeted therapies, sobering data were presented regarding therapy for NRAS-mutant and uveal subtypes, proving that the battle is far from won.

First Page Preview View Large
First page PDF preview
First page PDF preview
×